Page 298 - TNFlipTest

E56 Endocrinology References Toronto Notes 2019 References
Agus AZ. Etiology of hypercalcemia. Rose BD (editor). Waltham: UpToDate. 2010.
Agus AZ. Overview of metabolic bone disease. Rose BD (editor). Waltham: UpToDate. 2002.
American Diabetes Association. Management of dyslipidemia in adults with diabetes (position statement). Diabetes Care 2002;25:S74-77.
Anderson TJ, Gregoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2012;29:151- 167.
Arnold A. Classification and pathogenesis of the multiple endocrine neoplasia syndromes. Rose BD (editor). Waltham: UpToDate. 2002.
Braunwald E, Fauci AS, Kasper DL, et al. Harrison’s principles of internal medicine, vol 2. New York: McGraw Hill, 2001. Chapter: DM; p2109-2135.
Burman KD. Overview of thyroiditis. Rose BD (editor). Waltham: UpToDate. 2002.
Canadian Task Force on Preventive Health Care. Prevention of osteoporosis and osteoporotic fractures in post-menopausal women. CMAJ 2004;170:1665-1667.
Cheng A, Fantus IG. Oral antihyperglycemic therapy for type 2 DM. CMAJ 2005;172:213-226.
Collins R, Armitage J, Parish S, et al. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
Dayan CM. Interpretation of thyroid function tests. Lancet 2001;357:619-624.
Dawson-Hughes B, Gold DT, Rodbard HW, et al. Physician’s guide to prevention and treatment of osteoporosis. Washington: National Osteoporosis Foundation, 2003.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines. Can J Diabetes 2018;42(S1):S1-S296.
Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. NEJM 2013;368:1279-1290.
Genest J, Frohlich JJ, Fodor JG, et al. Recommendations of the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CMAJ 2003;168(9):921-4.
Greenspan FS, Garber DG. Basic and clinical endocrinology. New York: Lange Medical Books/McGraw Hill, 2001. 100-163, 201-272, 623-761.
Hemmingssen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 DM. Cochrane DB Syst Rev 6 2011;CD008143.
Hirsch IB, Paauw DS, Brunzell J. Inpatient management of adults with diabetes. Diabetes Care 1995;18:870-878.
KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Intern Suppl 2013;3:1-150.
Kitabachi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001;24:131-152.
Kronenberg HM, Larsen PR, Melmed S, et al. Williams textbook of endocrinology, 9th ed. Philadelphia: WB Saunders, 1998.
Morales A, Bebb RA, Manjoo P, et al. Canadian Men’s Health Foundation Multidisciplinary Guidelines Task Force on Testosterone Deficiency. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline. CMAJ 2015;187:1369-77
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
Orth DN. Evaluation of the response to ACTH in adrenal insufficiency. Rose BD (editor). Waltham: UpToDate. 2002.
Papaioannou A, Morin S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182(17):1864-1873.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEJM 2008;359: 2195–2207.
Rosen HN, Rosenblatt M. Overview of the management of osteoporosis in women. Rose BD (editor). Waltham: UpToDate. 2002.
Ross DS. Disorders that cause hypothyroidism. Rose BD (editor). Waltham: UpToDate. 2002.
Ryan EA. Pregnancy in diabetes. Med Clin of N Amer 1998;82:823-845.
Sabatine, MS. Pocket Medicine. Fifth edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2014.
Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. NEJM 2011;364:1728-1737.
Singer FR, Bone HG, Hosking DJ, et al. Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2014; 99 (12): 4408-4422. doi: 10.1210/jc.2014-2910.
Stone NJ, Robinson J, Lichtenstein AH et al. A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2013;00:000-000.
The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
Tsui E, Barnie A, Ross S, et al. Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. Diabetes Care 2001;24:1722-1727.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837- 853.
Weaver CM, Alexander DD, Boushey CJ et al. Calcium plus vitamin D supplementation and risk of fractures. Osteoporosis Int 2015;27:367-376.
Wing RR, Bolin P, Brancati F, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. NEJM 2013;369:145-154.
Young WF, Kaplan NM. Diagnosis and treatment of pheochromocytoma in adults. Rose BD (editor). Waltham: UpToDate. 2002.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. NEJM 2015;373:2117-2128.